EUVIMEDOpdag EUVIMED
Crossref

Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study

Jonathan Zurawski iD, Shahamat Tauhid, Brian C Healy, Renxin Chu, Maria K Houtchens, Youmna Jalkh, Samar Khalil, Molly Quattrucci, Farrah J Mateen, Salvatore Napoli, Syed Rizvi, Tarun Singhal and 1 more

Journal of Neuroimaging · 2025

DOI: 10.1111/jon.70032 ↗

At a glance

Journal article in Journal of Neuroimaging, 2025. Written by Jonathan Zurawski and 12 co-authors. Institution: Departments of Neurology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimag…. Major MEDLINE topics: Cladribine, Magnetic Resonance Imaging, Gray Matter, Immunosuppressive Agents. Cited 4 times so far (Crossref); 38 references. Funded by: EMD Serono.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Cladribine, an FDA‐approved disease‐modifying immunotherapy for multiple sclerosis (MS), penetrates the CSF and mitigates T cells and B cells, and thus may impact the development of cortical gray matter lesions (CLs) and leptomeningeal enhancement (LME). 7T MRI is a highly sensitive tool for monitoring these outcomes in relapsing‐remitting (RR) MS.

Methods

MS subjects ( n = 19, age [mean ± standard deviation]: 48.8 ± 10.0 years, 63.1% RRMS, 36.9% secondary progressive MS, Expanded Disability Status Scale [EDSS] score 4.1 ± 2.0) underwent 7T MRI with 0.7‐mm 3 voxels within a mean 1.9 months of oral cladribine initiation and ∼1 year later in this real‐world study. CLs and LME were quantified by an expert. Wilcoxon signed rank tests and paired t ‐tests compared baseline to follow‐up data.

Results

A total of 88.2% of subjects had CLs at baseline (mean 14.1 CLs/patient, range 1–77). No subjects accrued new CLs, and CL volume remained stable (0.33 ± 0.48 mL baseline vs. 0.31 ± 0.46 mL follow‐up, p = 0.22). LME was found in 88.9% of subjects at baseline. LME foci number was stable in seven (41.2%), increased in five (29.4%), and decreased in five (29.4%) subjects at follow‐up, but overall LME burden was stable (3.1 ± 1.8 vs. 3.2 ± 1.6 foci per subject, p = 1.0). No EDSS or timed 25‐foot walk change was noted (both p > 0.35). No subjects had clinical relapses or new T2 or gadolinium‐enhancing white matter lesions during the study.

Conclusion

These observational data suggest that cladribine therapy stabilizes cortical demyelination in MS over the first year of treatment. Overall, LME burden remained stable over 1 year; however, within‐subject resolution and accrual were noted.

Subjects

MeSH terms (MEDLINE)

CladribineMagnetic Resonance ImagingGray MatterImmunosuppressive AgentsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisHumansMaleFemaleMiddle AgedAdult

Author keywords

7T MRIcladribinecortical lesionsmultiple sclerosis

Substances

CladribineImmunosuppressive Agents

Authors and institutions

  • Departments of Neurology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimaging Research, Harvard Medical School, Boston, Massachusetts, USA.
  • Departments of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Departments of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Neurology Center of New England, Foxborough, Massachusetts, USA.
  • Multiple Sclerosis Center of Rhode Island, Brown University Medical School, Providence, Rhode Island, US.
  • Departments of Radiology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimaging Research, Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Jonathan Zurawski, Rohit Bakshi

Funding

  • EMD Serono

Cite

APA

Zurawski, J., Tauhid, S., Healy, B. C., Chu, R., Houtchens, M. K., Jalkh, Y., Khalil, S., Quattrucci, M., Mateen, F. J., Napoli, S., Rizvi, S., Singhal, T., & Bakshi, R. (2025). Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study. Journal of Neuroimaging. https://doi.org/10.1111/jon.70032

Vancouver

Zurawski J, Tauhid S, Healy BC, Chu R, Houtchens MK, Jalkh Y, et al. Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study. Journal of Neuroimaging. 2025. doi:10.1111/jon.70032

BibTeX
@article{Zurawski2025,
  author = {Zurawski, Jonathan and Tauhid, Shahamat and Healy, Brian C and Chu, Renxin and Houtchens, Maria K and Jalkh, Youmna and Khalil, Samar and Quattrucci, Molly and Mateen, Farrah J and Napoli, Salvatore and Rizvi, Syed and Singhal, Tarun and Bakshi, Rohit},
  title = {Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study},
  journal = {Journal of Neuroimaging},
  year = {2025},
  doi = {10.1111/jon.70032}
}
Start for free →